Download

Full Text

• Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [CrossRef]
• Munster, V.J.; Koopmans, M.; van Doremalen, N.; van Riel, D.; de Wit, E. A novel coronavirus emerging in China-key questions for impact assessment. N. Engl. J. Med. 2020, 382, 692–694. [CrossRef] [PubMed]
• Coperchinia, F.; Chiovatoa, L.; Crocea, L.; Magria, F.; Rotondia, M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020, 53, 25–32. [CrossRef]
• Castelli, V.; Cimini, A.; Ferri, C. Cytokine Storm in COVID-19: When You Come Out of the Storm, You Won’t Be the Same Person Who Walked in. Front. Immunol. 2020, 11. [CrossRef] [PubMed]
• Catanzaro, M.; Fagiani, F.; Racchi, M.; Corsini, E.; Govoni, S.; Lanni, C. Immune response in COVID-19: Addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct. Target. Ther. 2020, 5, 1–10. [CrossRef]
• Carsana, L.; Sonzogni, A.; Nasr, A.; Rossi, R.S.; Pellegrinelli, A.; Zerbi, P.; Rech, R.; Colombo, R.; Antinori, S.; Corbellino, M.; et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: A two-centre descriptive study. Lancet Infect. Dis. 2020, 20, 1135–1140. [CrossRef]
• Steven, S.; Frenis, K.; Oelze, M.; Kalinovic, S.; Kuntic, M.; Jimenez, M.T.B.; Vujacic-Mirski, K.; Helmstädter, J.; Kröller-Schön, S.; Münzel, T.; et al. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. Oxidative Med. Cell. Longev. 2019, 2019, 1–26. [CrossRef]
• Zuo, L.; Prather, E.R.; Stetskiv, M.; Garrison, D.E.; Meade, J.R.; Peace, T.I.; Zhou, T. Inflammaging and oxidative stress in human diseases: From molecular mechanisms to novel treatments. Int. J. Mol. Sci. 2019, 20, 4472. [CrossRef]
• Guerrero, C.A.; Acosta, O. Inflammatory and oxidative stress in rotavirus infection. World J. Virol. 2016, 5, 38–62. [CrossRef]
• Jones. D.P. Redefining oxidative stress. Antioxid. Redox Signal 2006, 8, 1865–1879.
• Ito, F.; Sono, Y.; Ito, T. Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxidative Stress in Diabetes, Atherosclerosis, and Chronic Inflammation. Antioxidants 2019, 8, 72. [CrossRef] [PubMed]
• Cecchini, R.; Cecchini, A.L. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. Med Hypotheses 2020, 143, 110102. [CrossRef]
• Zhang, H.; Penninger, J.M.; Li, Y.; Zhong, N.; Slutsky, A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020, 46, 586–590. [CrossRef]
• Brojakowska, A.; Jagat Narula, B.A.; Shimony, R.; Bander, J. Clinical implications of SARS-CoV-2 interaction with renin angiotensin system JACC review topic of the week. J. Am. Coll. Cardiol. 2020, 75, 3085–3095. [CrossRef] [PubMed]
• Rabelo, L.A.; Alenina, N.; Bader, M. ACE2–angiotensin-(1–7)–Mas axis and oxidative stress in cardiovascular disease. Hypertens. Res. 2011, 34, 154–160. [CrossRef] [PubMed]
• Wen, H.; Gwathmey, J.K.; Xie, L.-H. Oxidative stress-mediated effects of angiotensin II in the cardiovascular system. World J. Hypertens. 2012, 2, 34–44. [CrossRef] [PubMed]
• Lippi, G.; Mattiuzzi, C. Hemoglobin value may be decreased in patients with severe coronavirus disease 2019. Hematol. Transfus. Cell Ther. 2020, 42, 116–117. [CrossRef]
• Vasoncellos, I.R.C.; Dutra, F.F.; Siqueira, M.S.; Paula-Neto, H.A.; Dahan, J.; Kiarely, E.; Carneiro, L.A.M.; Bozza, M.T.; Travassos, L.H. Protein aggregation as a cellular response to oxidative stress induced by heme and iron. Proc. Natl. Acad. Sci. USA 2016, 113, 7474–7482.
• Cavezzi, A.; Troiani, E.; Corrao, S. COVID-19: Hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin. Pr. 2020, 10, 1271. [CrossRef]
• Vallelian, F.; Schaer, C.A.; Deuel, J.W.; Ingoglia, G.; Humar, R.; Buehler, P.W.; Schaer, D.J. Revisiting the putative role of heme as a trigger of inflammation. Pharmacol. Res. Perspect. 2018, 6, e00392. [CrossRef]
• Sultan, S.; Sultan, M. COVID-19 cytokine storm and novel truth. Med. Hypotheses 2020, 144, 109875. [CrossRef]
• Huertas, A.; Montani, D.; Savale, L.; Pichon, J.; Tu, L.; Parent, F.; Guignabert, C.; Humbert, M. Endothelial cell dysfunction: A major player in SARS-CoV-2 infection (COVID-19)? Eur. Respir. J. 2020, 56, 2001634. [CrossRef]
• Froldi, G.; Dorigo, P. Endothelial dysfunction in Coronavirus disease 2019 (COVID-19): Gender and age influences. Med Hypotheses 2020, 144, 110015. [CrossRef]
• Heiss, C.; Rodriguez-Mateos, A.; Kelm, M. Central Role of eNOS in the Maintenance of Endothelial Homeostasis. Antioxidants Redox Signal 2015, 22, 1230–1242. [CrossRef] [PubMed]
• Schulz, E.; Gori, T.; Münzel, T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens. Res. 2011, 34, 665–673. [CrossRef] [PubMed]
• Scioli, M.G.; Storti, G.; D’Amico, F.; Guzmán, R.R.; Centofanti, F.; Doldo, E.; Miranda, E.M.C.; Orlandi, A. Oxidative Stress and New Pathogenetic Mechanisms in Endothelial Dysfunction: Potential Diagnostic Biomarkers and Therapeutic Targets. J. Clin. Med. 2020, 9, 1995. [CrossRef] [PubMed]
• Delgado-Roche, L.; Mesta, F. Oxidative stress as key player in severe acute respiratory syndrome coronaivirus (SARS-COV) infection. Arch. Med. Res. 2020, 51, 384–387. [CrossRef] [PubMed]
• Derouiche, S. Oxidative stress associated SARS-CoV-2 (COVID-19) increases the severity of lung disease—A systematic review. Infect. Dis. Epidemiol. 2020. [CrossRef]
• Pincemail, J.; Defraigne, J.; Cheramy–Bien, J.; Dardenne, N.; Donneau, A.; Albert, A.; Labropoulos, N.; Sakalihasan, N. On the potential increase of the oxidative stress status in patients with abdominal aortic aneurysm. Redox Rep. 2012, 17, 139–144. [CrossRef]
• Pincemail, J.; Vanbelle, S.; Gaspard, U.; Collette, G.; Haleng, J.; Cheramy-Bien, J.; Charlier, C.; Chapelle, J.; Giet, D.; Albert, A.; et al. Effect of different contraceptive methods on the oxidative stress status in women aged 40–48 years from the ELAN study in the province of Liège, Belgium. Hum. Reprod. 2007, 22, 2335–2343. [CrossRef]
• Joël, P.; Mouna-Messaouda, K.; Jean-Paul, C.-B.; Jean-Olivier, D.; Smail, M. Electrochemical Methodology for Evaluating Skin Oxidative Stress Status (SOSS). Diseases 2019, 7, 40. [CrossRef]
• Lindblad, M.; Tveden-Nyborg, P.; Lykkesfeldt, J. Regulation of Vitamin C Homeostasis during Deficiency. Nutrients 2013, 5, 2860–2879. [CrossRef]
• Chiscano-Carnon, L.; Ruiz-Rodriguez, J.C.; Rulz-Sanmartin, A.; Roca, O.; Ferrer, R. Vitamin C levels in patients with SARS-CoV-2 associated acute respiratory distress syndrome. Crit. Care 2020, 24, 1–3. [CrossRef]
• Singer, P.; Blaser, A.R.; Berger, M.M.; Alhazzani, W.; Calder, P.C.; Casaer, M.P.; Hiesmayr, M.; Mayer, K.; Montejo, J.C.; Pichard, C.; et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin. Nutr. 2019, 38, 48–79. [CrossRef] [PubMed]
• Carr, A.C.; Rosengrave, P.C.; Bayer, S.; Chambers, S.; Mehrtens, J.; Shaw, G.M. Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes. Crit. Care 2017. [CrossRef]
• Padayatty, S.J.; Sun, H.; Wang, Y.; Riordan, H.D.; Hewitt, S.M.; Katz, A.; Wesley, R.A.; Levine, M. Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use. Ann. Intern. Med. 2004, 140, 533–537. [CrossRef]
• Nabzdyk, C.S.; Bittner, E.A. Vitamin C in the critically ill—Indications and controversies. World J. Crit. Care Med. 2018, 7, 52–61. [CrossRef] [PubMed]
• Hemilä, H.; Chalker, E. Vitamin C Can Shorten the Length of Stay in the ICU: A Meta-Analysis. Nutrients 2019, 11, 708. [CrossRef] [PubMed]
• Boretti, A.; Banik, B.K. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition 2020, 12, 100190. [CrossRef]
• Erol, A. High-dose Intravenous Vitamin C Treatment for COVID-19. OSF Preprints 2020. [CrossRef]
• Zhang, J.; Rao, X.; Li, Y.; Zhu, Y.; Liu, F.; Guo, G.; Luo, G.; Meng, Z.; De Backer, D.; Xiang, H.; et al. High-dose vitamin C infusion for the treatment of critically ill COVID-19. Ann. Intens. Care 2020. on press.
• Dröge, W.; Breitkreutz, R. Glutathione and immune function. Proc. Nutr. Soc. 2000, 59, 595–600. [CrossRef]
• Morris, D.; Khurasany, M.; Nguyen, T.; Kim, J.; Guilford, F.; Mehta, R.; Gray, D.; Saviola, B.; Venketaraman, V. Glutathione and infection. Biochim. et Biophys. Acta (BBA) Gen. Subj. 2013, 1830, 3329–3349. [CrossRef]
• Townsend, D.; Tewa, K.D.; Tapierob, H. The importance of glutathione in human disease. Biomed Pharm. 2003, 57, 145–155. [CrossRef]
• Morris, P.E.; Bernard, G.R.; Bernard, C.R. Significance of Glutathione in Lung Disease and Implications for Therapy. Am. J. Med Sci. 1994, 307, 119–127. [CrossRef]
• Polonikov, A. Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients. ACS Infect. Dis. 2020, 6, 1558–1562. [CrossRef] [PubMed]
• Horowitz, R.I.; Freeman, P.R.; Bruzzese, J. Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases. Respir. Med. Case Rep. 2020, 30, 101063. [CrossRef]
• Poe, F.L.; Corn, J. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Med. Hypotheses 2020, 143, 109862. [CrossRef]
• Jorge-Aarón, R.-M.; Moo-Puc, R.E. N-acetylcysteine as a potential treatment for COVID-19. Futur. Microbiol. 2020, 15, 959–962. [CrossRef]
• De Flora, S.; Balansky, R.; La Maestra, S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J. 2020, 34, 13185–13193. [CrossRef] [PubMed]
• Turell, L.; Radi, R.; Alvarez, B. The thiol pool in human plasma: The central contribution of albumin to redox processes. Free. Radic. Biol. Med. 2013, 65, 244–253. [CrossRef]
• Bharadwaj, S.; Ginoya, S.; Tandon, P.; Gohel, T.D.; Guirguis, J.; Vallabh, H.; Jevenn, A.; Hanouneh, I. Malnutrition vs nutritional assessment. Gastroenterol Rep. 2016, 4, 272–280.
• Serafini, M.; Del Rio, D. Understanding the association between dietary antioxidants, redox status and disease: Is the Total Antioxidant Capacity the right tool? Redox Rep. 2004, 9, 145–152. [CrossRef]
• Bartosz, G. Non-enzymatic antioxidant capacity assays: Limitations of use in biomedicine. Free. Radic. Res. 2010, 44, 711–720. [CrossRef] [PubMed]
• Carrión-García, C.J.; Guerra-Hernández, E.J.; García-Villanova, B.; Serafini, M.; Sánchez, M.-J.; Amiano, P.; Molina-Montes, E. Plasma Non-Enzymatic Antioxidant Capacity (NEAC) in Relation to Dietary NEAC, Nutrient Antioxidants and InflammationRelated Biomarkers. Antioxidants 2020, 9, 301. [CrossRef] [PubMed]
• Huang, Z.; Rose, A.H.; Hoffmann, P.R. The Role of Selenium in Inflammation and Immunity: From Molecular Mechanisms to Therapeutic Opportunities. Antioxid. Redox Signal 2012, 16, 705–743. [CrossRef] [PubMed]
• Moghaddam, A.; Heller, R.A.; Sun, Q.; Seelig, J.; Cherkezov, A.; Seibert, L.; Hackler, J.; Seemann, P.; Diegmann, J.; Pilz, M.; et al. Selenium Deficiency Is Associated with Mortality Risk from COVID-19. Nutrients 2020, 12, 2098. [CrossRef] [PubMed]
• Gaetke, L.M.; Chow, C.K. Copper toxicity, oxidative stress and antioxidant nutrients. Toxicology 2003, 189, 147–163. [CrossRef]
• Prasad, A.S. Zinc in Human Health: Effect of Zinc on Immune Cells. Mol. Med. 2008, 14, 353–357. [CrossRef]
• Jarosz, M.; Olbert, M.; Wyszogrodzka, G.; Młyniec, K.; Librowski, T. Antioxidant and anti-inflammatory effects of zinc. Zincdependent NF-κB signaling. Inflammopharmacology 2017, 25, 11–24. [CrossRef] [PubMed]
• Guo, C.-H.; Chen, P.-C.; Yeh, M.-S.; Hsiung, D.-Y.; Wang, C.-L. Cu/Zn ratios are associated with nutritional status, oxidative stress, inflammation, and immune abnormalities in patients on peritoneal dialysis. Clin. Biochem. 2011, 44, 275–280. [CrossRef]
• Ozturk, P.; Kurutas, E.B.; Ataseven, A. Copper/zinc and copper/selenium ratios, and oxidative stress as biochemical markers in recurrent aphthous stomatitis. J. Trace Elements Med. Biol. 2013, 27, 312–316. [CrossRef] [PubMed]
• Malavolta, M.; Piacenza, F.; Basso, A.; Giacconi, R.; Costarelli, L.; Mocchegiani, E. Serum copper to zinc ratio: Relationship with aging and health status. Mech. Ageing Dev. 2015, 151, 93–100. [CrossRef] [PubMed]
• Milanino, R.; Marrella, M.; Gasperini, R.; Pasqualicchio, M.; Velo, G. Copper and zinc body levels in inflammation: An overview of the data obtained from animal and human studies. Inflamm. Res. 1993, 39, 195–209. [CrossRef]
• Mezzetti, A.; Pierdomenico, S.D.; Costantini, F.; Romano, F.; De Cesare, D.; Cuccurullo, F.; Imbastaro, T.; Riario-Sforza, G.; Di Giacomo, F.; Zuliani, G.; et al. Copper/zinc ratio and systemic oxidant load: Effect of aging and aging-related degenerative diseases. Free. Radic. Biol. Med. 1998, 25, 676–681. [CrossRef]
• Guo, C.-H.; Wang, C.-L. Effects of Zinc Supplementation on Plasma Copper/Zinc Ratios, Oxidative Stress, and Immunological Status in Hemodialysis Patients. Int. J. Med. Sci. 2013, 10, 79–89. [CrossRef]
• Shen, Y.; Yang, T.; Guo, S.; Li, X.; Chen, L.; Wang, T.; Wen, F.-Q. Increased Serum ox-LDL Levels Correlated with Lung Function, Inflammation, and Oxidative Stress in COPD. Mediat. Inflamm. 2013, 2013, 1–5. [CrossRef]
• Hulthe, J. Antibodies to oxidized LDL in atherosclerosis development—clinical and animal studies. Clin. Chim. Acta 2004, 348, 1–8. [CrossRef]
• Gozalbo-Rovira, R.; Gimenez, E.; Latorre, V.; Francés-Gómez, C.; Albert, E.; Buesa, J.; Marina, A.; Blasco, M.L.; Signes-Costa, J.; Rodríguez-Díaz, J.; et al. SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. J. Clin. Virol. 2020, 131, 104611. [CrossRef] [PubMed]
• Loria, V.; Dato, I.; Graziani, F.; Biasucci, L.M. Myeloperoxidase: A New Biomarker of Inflammation in Ischemic Heart Disease and Acute Coronary Syndromes. Mediat. Inflamm. 2008, 2008, 1–4. [CrossRef]
• Vlasova, I.I.; Sokolov, A.V.; Kostevich, V.A.; Mikhalchik, E.V.; Vasilyev, V.B. Myeloperoxidase-Induced Oxidation of Albumin and Ceruloplasmin: Role of Tyrosines. Biochemestry (Moscow) 2019, 84, 652–662. [CrossRef] [PubMed]
• Rahmani-Kukia, N.; Abbasi, A.; Pakravan, N.; Hassan, Z.M. Measurement of oxidized albumin: An opportunity for diagnoses or treatment of COVID-19. Bioorganic Chem. 2020, 105, 104429. [CrossRef]
• Schorah, C.J.; Downing, C.; Piripitsi, A.; Gallivan, L.; Al-Hazaa, A.H.; Sanderson, M.J.; Bodenham, A. Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill patients. Am. J. Clin. Nutr. 1996, 63, 760–765. [CrossRef]
• Metnitz, P.G.H.; Bartens, C.; Fischer, M.; Fridrich, P.; Steltzer, H.; Druml, W. Antioxidant status in patients with acute respiratory distress syndrome. Intensiv. Care Med. 1999, 25, 180–185. [CrossRef]
• Ruocco, M.A.C.; Cechinatti, E.D.P.; Barbosa, F.; Navarro, A.M. Zinc and selenium status in critically ill patients according to severity stratification. Nutrients 2018, 45, 85–89. [CrossRef]
• Zhang, J.; Xie, B.; Hashimoto, K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav. Immun. 2020, 87, 59–73. [CrossRef]
• Carr, A.C. Micronutrient status of COVID-19 patients: A critical consideration. Crit. Care 2020, 24, 349. [CrossRef]
• Jing-Zhang, W.; Rui-Ying, Z.; Bai, J. An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients. Int. J. Cardiol. 2020, 312, 137–138.
• Loffredo, L.; Violi, F. COVID-19 and cardiovascular injury: A role for oxidative stress and antioxidant treatment? Int. J. Cardiol. 2020, 312, 136. [CrossRef]
• Kassi, E.N.; Papavassiliou, K.A.; Papavassiliou, A.G. Defective Anti-oxidant System: An Aggravating Factor for COVID-19 Patients Outcome? Arch. Med Res. 2020, 51, 726–727. [CrossRef] [PubMed]
• Zhang, L.; Liu, Y. Potential interventions for novel coronavirus in China: A systematic review. J. Med Virol. 2020, 92, 479–490. [CrossRef] [PubMed]
• Marseglia, L.; Manti, S.; D’Angelo, G.; Nicotera, A.; Parisi, E.; Di Rosa, G.; Gitto, E.; Arrigo, T. Oxidative Stress in Obesity: A Critical Component in Human Diseases. Int. J. Mol. Sci. 2014, 16, 378–400. [CrossRef] [PubMed]
• Oguntibeju, O.O. Type 2 diabetes mellitus, oxidative stress and inflammation: Examining the links. Int. J. Physiol. Pathophysiol. Pharmacology 2019, 11, 45–63.
• González, J.; Valls, N.; Brito, R.; Rodrigo, R. Essential hypertension and oxidative stress: New insights. World J. Cardiol. 2014, 6, 353–366. [CrossRef]
• Canoy, D.; Wareham, N.; Welch, A.; Bingham, S.; Luben, R.; Day, N.; Khaw, K.-T. Plasma ascorbic acid concentrations and fat distribution in 19 068 British men and women in the European Prospective Investigation into Cancer and Nutrition Norfolk cohort study. Am. J. Clin. Nutr. 2005, 82, 1203–1209. [CrossRef]
• Sinclair, A.; Taylor, P.; Lunec, J.; Girling, A.; Barnett, A. Low Plasma Ascorbate Levels in Patients with Type 2 Diabetes Mellitus Consuming Adequate Dietary Vitamin C. Diabet. Med. 1994, 11, 893–898. [CrossRef]
• Wilson, R.; Willis, J.; Gearry, R.; Skidmore, P.; Fleming, E.; Frampton, C.; Carr, A. Inadequate Vitamin C Status in Prediabetes and Type 2 Diabetes Mellitus: Associations with Glycaemic Control, Obesity, and Smoking. Nutrients 2017, 9, 997. [CrossRef]
• Kurl, S.; Tuomainen, T.; Laukkanen, J.A.; Nyyssonen, K.; Lakka, T.; Sivenius, J.; Salonen, J. Plasma Vitamin C Modifies the Association Between Hypertension and Risk of Stroke. Stroke 2002, 33, 1568–1573. [CrossRef] [PubMed]